港股创新药概念股走低，多只港股创新药相关ETF跌超2%

Group 1 - The core viewpoint of the news indicates a decline in Hong Kong innovative pharmaceutical stocks, with notable drops in companies such as Hansoh Pharmaceutical, which fell over 4%, and others like Innovent Biologics, China Biologic Products, and 3SBio, which dropped over 3% [1] - Multiple Hong Kong innovative pharmaceutical-related ETFs also experienced declines, with losses exceeding 2% [1] Group 2 - Specific ETF performance includes: - E Fund Hong Kong Stock Connect Medical ETF (520850) at 0.978, down 2.49% - Hong Kong Stock Connect Innovative Drug ETF (159570) at 1.690, down 2.20% - Hong Kong Innovative Drug ETF Fund (520700) at 1.652, down 2.07% - Hong Kong Stock Innovative Drug 50 ETF (513780) at 1.713, down 2.06% - Harvest Hong Kong Stock Connect Innovative Drug ETF (520970) at 0.924, down 2.01% [2] - Some brokerages suggest that core assets in innovative drugs will continue to rise, with new opportunities emerging in areas like small nucleic acids and in vivo CAR technologies [2] - The long-term trend of innovative drug business development (BD) is highlighted as a pathway for Chinese innovative drug capabilities to gain recognition on the global stage, with core assets licensed to multinational corporations (MNCs) expected to realize value as clinical progress continues [2]